The range of patients who can use Entresto (Sacubitril/Valsartan), a treatment for chronic heart failure of Novartis Korea, has become a little clearer. Until now, there has been a debate over the normal range of left ventricular ejection rates, with "chronic heart failure patients with decreased left ventricular contraction function."

On February 14, the MFDS changed the effectiveness of Enresto, a heart failure treatment of Sacubitril/Valsartan drugs, and Xnepri by Sandoz.


The efficacy at the time of Enresto approval in 2016 were ▲ chronic heart failure: decreased risk of death due to cardiovascular disease and hospitalization due to heart failure in patients with left ventricular